Fairvalue-Calculator Fairvalue-Calculator
EN DE

Heron Therapeutics, Inc (HRTX) Fair Value & Analysis

Healthcare · US · Market cap $79.0M

Price$0.4186
Fair Value$0.3400
Upside-18.8%
Quality95/100
Evidence: Low Range $0.2600 – $0.4300

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Heron Therapeutics, Inc (HRTX) currently trades at $0.4186, while our model-based Fair Value estimate is $0.3400 — implying the stock looks roughly 18.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dua…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Heron Therapeutics, Inc (HRTX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $0.3400 versus a price of $0.4186 — about −19% (overvalued). Model-based estimate, not financial advice.
What is the fair value of HRTX?
Our 21-model fair value for Heron Therapeutics, Inc is $0.3400 (as of Jun 24, 2026), built from audited fundamentals. The current price is $0.4186.
What is the quality score of HRTX?
Heron Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.